Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov853810.25208/vdv8538REVIEWSОБЗОР ЛИТЕРАТУРЫReview ArticlePathogenetic substantiation of combination therapy for rosaceaПатогенетическое обоснование комбинированной терапии розацеаhttps://orcid.org/0000-0002-7625-05038771-4990KubanovAlexey A.КубановАлексей Алексеевич
Russian Federation

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

д.м.н., профессор, академик РАН

alex@cnikvi.ruhttps://orcid.org/0000-0003-4169-41287634-5521PlakhovaXenia I.ПлаховаКсения Ильинична
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

plahova@cnikvi.ruhttps://orcid.org/0000-0003-3662-99548721-9424KondrakhinaIrina N.КондрахинаИрина Никифоровна
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

kondrakhina77@gmail.comhttps://orcid.org/0009-0005-3155-0923VolkovaSofia V.ВолковаСофья Валерьевна
Russian Federation

Dermatovenerologist

врач-дерматовенеролог

Doctordermsv@yandex.ruState Research Center of Dermatovenereology and CosmetologyГосударственный научный центр дерматовенерологии и косметологии191020231212202399513213004202326092023Copyright ©; 2023, Kubanov A.A., Plakhova X.I., Kondrakhina I.N., Volkova S.V.Copyright ©; 2023, Кубанов А.А., Плахова К.И., Кондрахина И.Н., Волкова С.В.2023Kubanov A.A., Plakhova X.I., Kondrakhina I.N., Volkova S.V.Кубанов А.А., Плахова К.И., Кондрахина И.Н., Волкова С.В.https://creativecommons.org/licenses/by-nc/4.0https://vestnikdv.ru/jour/article/view/8538

Rosacea is a chronic inflammatory dermatosis predominantly damage to the skin of the face, which has a significant negative impact on the quality patients’ lives. The main goal of treatment is to achieve the most complete remission. However, due to the fact that the pathogenesis of the disease is not fully understood, the search for new methods of treatment is especially relevant. Combined use pulsed dye laser and ivermectin drug is presented as alternative pathogenetically substantiated method of therapy. The purpose of the study is to characterize immune disorders and the role of cytokines in the pathogenesis of rosacea, as well as the possibilities of combination therapy based on literature data. An analysis of literature sources from the MedLine, Pubmed, eLibrary databases for the period from 2002 to 2022 was carried out, using the keywords “ivermectin”, “pulsed dye laser”, “rosacea”, “cytokines”, “ivermectin” , “Pulsed Dye Laser”, “rosacea”, “cytokines”.

Розацеа является хроническим воспалительным дерматозом с преимущественным поражением кожи лица, оказывающим существенное негативное влияние на качество жизни пациентов. Основная цель лечения — достижение максимально полной ремиссии. В связи с тем, что патогенез заболевания в полной мере не изучен, поиск новых методов лечения особенно актуален. Комбинированное использование импульсного лазера на красителях и препарата ивермектин представляется в качестве альтернативного патогенетически обоснованного метода терапии. Цель исследования — охарактеризовать иммунные нарушения и роль цитокинов в патогенезе розацеа, а также возможности комбинированной терапии на основании литературных данных. Проведен анализ литературных источников из баз данных MedLine, Pubmed, eLibrary за период с 2002 по 2022 г. по ключевым словам: «ивермектин», «импульсный лазер на красителях», «розацеа», «цитокины», «ivermectin», «Pulsed Dye Laser», «rosacea», «cytokines».

rosaceaivermectinpulsed dye lasercytokinescombination therapyрозацеаивермектинимпульсный лазер на красителяхцитокиныкомбинированная терапияКубанова А.А., Кисина В.И. Рациональная фармакотерапия заболеваний кожи и инфекций, передаваемых половым путем. М.: Литерра, 2005. Т. VIII. С. 387–390. [Kubanova AA, Kisina VI. Rationale for drug therapy of skin disorders and sexually transmitted diseases. Moscow: Literra; 2005. Vol. VIII. Р. 387–390. (In Russ.)]Иванов О.Л., Молочков В.А., Кряжева С.С., и др. Кожные и венерические болезни: справочник. М.: Медицина, 2007. С. 240–241. [Ivanov OL, Molochkov VA, Kryazheva SS, et al. Skin and venereal diseases: a reference book. Moscow: Medicine; 2007. Р. 240–241. (In Russ.)]Tan J, Berg M. Rosaceа: current state of epidemiology. J Am Acad Dermatol. 2013;69(6Suppl1):S27–35. doi: 10.1016/j.jaad.2013.04.043Powell FC. Rosacea. N Engl J Med. 2005;352(8):793–803. doi: 10.1056/NEJMcp042829Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282–289. doi: 10.1111/bjd.16481Самцов А.В., Аравийская Е.Р. Акне и розацеа: монография. М.: Фармтек, 2021. C. 290–314. [Samtsov AV, Araviyskaya EA. Acne and rosacea: monography. Moscow: Pharmtek; 2021. P. 290–314. (In Russ.)]Юцковская Я.А., Кусая Н.В., Ключник С.Б. Обоснование патогенетической терапии при акнеподобных дерматозах, осложненных клещевой инвазией Demodex folliculorum. Клиническая дерматология и венерология. 2010;8(3):60–63. [Iutskovskaia IaA, Kusaia NV, Kliuchnik SB. Rationale for pathogenetic therapy for acne-like dermatoses complicated by Demodex folliculorum infestation. Klinicheskaya Dermatologiya i Venerologiya. 2010;8(3):60–63. (In Russ.)]Хэбиф Т.П. Кожные болезни: Диагностика и лечение: пер. 3-го англ. изд. М.: МЕДпресс-информ, 2006. С. 106–107. [Khebif T.P. Skin diseases: Diagnosis and treatment. Transl. from 3rd engl. ed. Moscow: MEDpress-inform; 2006. Р. 106–107. (In Russ.)]Вольф К., Голдсмит Л.А., Кац С.И., и др. Дерматология Фицпатрика в клинической практике: пер. с англ.: в 3 т. / под ред. А.А. Кубановой и др. М.: Изд-во Панфилова; БИНОМ, 2012. Т. 1. С. 769–778. [Wolf K, Goldsmith LA, Katz SI, et al. Fitzpatrick dermatology in clinical practice. Transl. from English. Ed. by Kubanova AA. Moscow: Panfilov Publishing House: BINOM; 2012. Vol. 1. Р. 769–778. (In Russ.)]Abram K, Silm H, Maaroos H-I, Oona M. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol. 2010;24(5):565–571. doi: 10.1111/j.1468-3083.2009.03472.xvan Zuuren EJ. Rosacea. N Engl J Med. 2017;377(18):1754–1764. doi: 10.1056/NEJMcp1506630Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):148–155. doi: 10.1016/j.jaad.2017.08.037Abram K, Silm H, Oona M. Prevalence of rosacea in an Estonian working population using a standard classification. Acta Derm Venereol. 2010;90(3):269–273. doi: 10.2340/00015555-0856Прохоренков В.И., Михель Д.В., Гузей Т.Н. Розацеа: современные аспекты этиологии и патогенеза. Клиническая дерматология и венерология. 2015;14(1):4–11. [Prokhorenkov VI, Mikhel’ DV, Guzeĭ TN. Rosacea: modern aspects of the etiology and pathogenesis. Klinicheskaya Dermatologiya i Venerologiya. 2015;14(1):4–11. (In Russ.)] doi: 10.17116/klinderma201514-11van der Linden MM, van Rappard DC, Daams JG, Sprangers MA, Spuls PI, de Korte J. Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol. 2015;95(4):395–400. doi: 10.2340/00015555-1976Bewley A, Fowler J, Schöfer H, Kerrouche N, Rives V. Erythema of rosacea impairs quality of life: results of a meta-analysis. Dermatol Ther (Heidelb). 2016;6(2):237–247. doi: 10.1007/s13555-016-0106-9Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Patients with rosacea have increased risk of depression and anxiety disorders: a Danish nationwide cohort study. Dermatology. 2016;232(2):208–213. doi: 10.1159/000444082Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients with rosacea. J Eur Acad Dermatol Venereol. 2017;31(1):163–168. doi: 10.1111/jdv.13748Шаршукова А.А., Круглова Л.С., Котенко К.В., Софинская Г.В. Этиопатогенез и возможности лазеротерапии эритематозно-телеангиэктатического подтипа розацеа. Физиотерапия, бальнеология и реабилитация. 2017;16(6):284–290. [Sharshunova AA, Kruglova LS, Kotenko KV, Sofinskaya GV. Etiopathogenesis and the opportunities of laserotherapy of erythemato-teleangiectatic rosacea subtype. Fizioterapiya, Bal’neologiya i Reabilitatsiya = Russian Journal of the Physical Therapy, Balneotherapy and Rehabilitation. 2017;16(6):284–290. (In Russ.)] doi: 10.18821/1681-3456-2017-16-6-284-290Эрнандес Е.И., Альбанова В.И., Калашникова Н.Г., и др. Розацеа и купероз в практике косметолога. М.: Косметика и медицина, 2021. С. 14–26. [Hernandez EI, Albanova VI, Kalashnikova NG, et al. Rosacea and couperosis in the practice of a cosmetologist. Moscow: Cosmetics and Medicine; 2021. Р. 387–390. (In Russ.)].Потекаев Н.Н., Львов А.Н., Хлыстова Е.А., Кочетков М.А. Первый опыт применения ивермектина и бримонидина тартрата у пациентов с розацеа (клинические наблюдения). Клиническая дерматология и венерология. 2017;16(2):117–125. [Potekaev NN, Lvov AN, Hlystova EA, Kochetkov MA. First experience of using ivermectin and brimonidine tartrate in patients with rosacea: case studies. Klinicheskaya Dermatologiya i Venerologiya. 2017;16(2):117–125. (In Russ.)] doi: 10.17116/klinderma2017162117-125Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91(3Suppl):1–8.Давыдова А.В., Бакулев А.Л., Моррисон А.В., Леонова М.А. Молекулярные механизмы патогенеза розацеа (обзор). Саратовский научно-медицинский журнал. 2013;9(3):561–565. [Davydova AV, Bakulev AL, Morrison AV, et al. Molecular mechanisms of rosacea pathogenesis (review). Saratov Journal of Medical Scientific Research. 2013;9(3):561–565. (In Russ.)]Кетлинский С.А., Симбирцев А.С. Цитокины. СПб.: Фолиант, 2008. С. 5, 118, 191. [Ketlinsky SA, Simbirtsev AS. Cytokines. Saint Petersburg: Foliant; 2008. Р. 5, 118, 191. (In Russ.)]Gerber PA, Buhren BA, Steinhoff M, Homey B. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15(1):40–47. doi: 10.1038/jidsymp.2011.9Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, Carlavan I, et al. Molecular and Morphological Characterization of Inflammatoty Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways. J Invest Dermatol. 2015;135(9):2198–2208. doi: 10.1038/jid.2015.141Dajnoki Z, Béke G, Kapitány A, Mócsai G, Gáspár K, Rühl R, et al. Sebaceous gland-rich skin is characterized by TSLP expression and distinct immune surveillance which is disturbed in rosacea. J Invest Dermatol. 2017;137(5):1114–1125. doi: 10.1016/j.jid.2016.12.025Shih Y-H, Xu J, Kumar A, Li R, Chang ALS. Alterations of immune and keratinization gene expression in papulopustular rosacea by whole transcriptome analysis. J Invest Dermatol. 2020;140(5):1100–1103.е4. doi: 10.1016/j.jid.2019.09.021Симбирцев А.С. Биология семейства интерлейкина-1 человека. Иммунология. 1998;6:9–17. [Simbircev AS. Biology of the human interleukin-1 family. Immunology. 1998;6:9–17. (In Russ.)]Casas C, Paul C, Lahfa M, Livideanu B, Lejeune O, Alvarez-Georges S, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21(12):906–910. doi: 10.1111/exd.12030Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Nardo AD. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014;134(11):2728–2736. doi: 10.1038/jid.2014.222Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7:F1000. Faculty Rev-1885. doi: 10.12688/f1000research.16537.1Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol. 2016;175(5):892–901. doi: 10.1111/bjd.14703Унт Д.В., Лобов Г.И. Механизмы действия интерлейкина-1β и интерлейкина-2 на транспортную функцию лимфатических сосудов и лимфатических узлов. Журнал фундаментальной медицины и биологии. 2017;2:15–19. [Unt DV, Lobov GI. Mechanisms of action interleukin-1β and interleukin-2 on transport function of lymphatic vessels and lymph nodes. Journal of Fundamental Medicine and Biology. 2017;2:15–19. (In Russ.)]Varfolomeev E, Vucic D. Intracellular regulation of TNF activity in health and disease. Cytokine. 2018;101:26–32. doi: 10.1016/j.cyto.2016.08.035Ярмолик Е.С., Горецкая М.В., Хворик Д.Ф., Шулика В.Р. Характеристика показателей цитокинового статуса при комплексном лечении розацеа. Журнал Гродненского медицинского университета. 2016;1(53):39–44. [Yarmolik ES, Goretskaya MV, Khvorik DF, Shulika VRl. Characteristics of cytokine status indicators in the complex treatment of rosacea. Journal of Grodno Medical University. 2016;1(53):39–44. (In Russ.)]Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26(8):659–667. doi: 10.1111/exd.13143Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of VEGF expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 1995;270(21):12607–12613. doi: 10.1074/jbc.270.21.12607Gomaa AH, Yaar M, Eyada MM, Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol. 2007;34(10):748–753. doi: 10.1111/j.1600-0560.2006.00695.xOtrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol Dis. 2007;39(2):212–220. doi: 10.1016/j.bcmd.2007.04.001Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676. doi: 10.1038/nm0603-669Олисова О.Ю., Додина М.И., Кушлинский Н.Е. Роль фактора роста сосудистого эндотелия в патогенезе розацеа и его медикаментозная коррекция. Клиническая дерматология и венерология. 2012;10(1):49–55. [Olisova OIu, Dodina MI, Kushlinskiĭ NE. The role of vascular endothelial growth factor in pathogenesis of rosacea and its medicamental correction. Klinicheskaya Dermatologiya i Venerologiya. 2012;10(1):4955. (In Russ.)]Пинсон И.Я., Верхогляд И.В., Семочкин А.В. Современные представления об этиологии и патогенезе розацеа. Экспериментальная и клиническая дерматокосметология. 2012;5:21–24. [Pinson IYa, Verkhoglyad IV, Semochkin AV. Current ideas on the etiology and pathogenesis of rosacea. Experimental and clinical dermatocos metology. 2012;5:21–24. (In Russ.)]Amir AA, Vender R, Vender R. The role of IL-17 in papulopustular rosacea and future directions. J Cutan Med Surg. 2019;23(6):635–641. doi: 10.1177/1203475419867611Hayran Y, Şen O, Oğuz FE, Yücel C, Eren F, Çakmak SK, et al. Serum IL-17 levels in patients with rosacea. J Cosmet Dermatol. 2022;21(3):1147–1153. doi: 10.1111/jocd.14169Scheenstra MR, van Harten RM, Veldhuizen EJA, Haagsman HP, Coorens M. Cathelicidins Modulate TLR-Activation and Inflammation. Front Immunol. 2020;11:1137. doi: 10.3389/fimmu.2020.01137Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15(1):12–15. doi: 10.1038/jidsymp.2011.4Адаскевич В.П. Патогенетические факторы, клинические формы и методы терапии розацеа. Вестник ВГМУ. 2004:3(1):6–8. [Adaskevich VP. Pathogenetic factors, clinical forms and methods of therapy for rosacea. Vestnik of Vitebsk State Medical University. 2004:3(1):6–8. (In Russ.)]Адаскевич В.П., Козин В.М. Кожные и венерические болезни. М.: Мед. лит., 2006. С. 345–351. [Adaskevich VP, Kozin VM. Skin and venereal diseases. Moscow: Medical Literature; 2006. Р. 345–351. (In Russ.)]Бауманн Л. Косметическая дерматология. Принципы и практика: пер. с англ. / под ред. Н.Н. Потеваева. М.: МЕДпресс-информ, 2012. С. 257–258. [Baumann L. Cosmetic dermatology. Principles and practice. Transl. from English. Ed. by Potekaev NN. Moscow: MEDpress-inform; 2012. Р. 257–258. (In Russ.)]Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol. 1983;108(3):327–332. doi: 10.1111/j.1365-2133.1983.tb03972.xDahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45(5):723–730. doi: 10.1067/mjd.2001.116219Zip C. An update on the role of topical metronidazole in rosacea. Skin Therapy Lett. 2006;11(2):1–4.Tan JK, Girard C, Krol A, Murray HE, Papp KA, Poulin Y, et al. Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. J Cutan Med Surg. 2002;6(6):529–534. doi: 10.1007/s10227-001-0144-4Yoo J, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol. 2006;5(4):317–319.Frampton JE, Wagstaff AJ. Azelaic acid 15% gel: in the treatment of papulopustular rosacea. Am J Clin Dermatol. 2004;5(1):57–64. doi: 10.2165/00128071-200405010-00009Liu RH, Smith MK, Basta SA, Farmer ER. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142(8):1047–1052. doi: 10.1001/archderm.142.8.1047Gupta AK, Gover MD. Azelaic acid (15% gel) in the treatment of acne rosacea. Int J Dermatol. 2007;46(5):533–538. doi: 10.1111/j.1365-4632.2005.02769.xGollnick H, Layton A. Azelaic acid 15% gel in the treatment of rosacea. Expert Opin Pharmacother. 2008;9(15):2699–2706. doi: 10.1517/14656566.9.15.2699Gold LS, Del Rosso JQ, Kircik L, Bhatia ND, Hooper D, Nahm WK, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82(5):1166–1173. doi: 10.1016/j.jaad.2020.01.043Kim M, Kim J, Jeong S-W, Jo H, Woo YR, Park HJ. Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. Exp Dermatol. 2017;26(11):1143–1145. doi: 10.1111/exd.13381Li Y, Xie H, Deng Z, Wang B, Tang Y, Zhao Z, et al. Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis. Int Immunopharmacol. 2019;67:326–334. doi: 10.1016/j.intimp.2018.12.031Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007;91(2):226–229. doi: 10.1136/bjo.2006.101121Eckert MM, Gundin LN. Treatment of rosacea with topical ivermectin cream: a series of 34 cases. Dermatol Online J. 2016;22(8):13030/qt9ks1c48n.Steinhoff M, Vocanson M, Voegel JJ, Hacini-Rachinel F, Schäfer G. Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments. Adv Ther. 2016;33(9):1481–1501. doi: 10.1007/s12325-016-0380-zTaieb A, Khemis A, Ruzicka T, Barańska-Rybak W, Berth-Jones J, Schauber J, et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30(5):829–836. doi: 10.1111/jdv.13537Schaller M, Almeida LM, Bewley A, Cribier B, Dlova NC, Kautz G, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465-471. doi: 10.1111/bjd.15173Trave I, Merlo G, Cozzani E, Parodi A. Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatol Ther. 2019;32(6):e13093. doi: 10.1111/dth.13093Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol. 2005;44(12):981–988 doi: 10.1111/j.1365-4632.2004.02253.xZhang X, Song Y, Ci X, An N, Ju Y, Li H, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008;57(11):524–529. doi: 10.1007/s00011-008-8007-8Raedler LA. Soolantra (Ivermectin) 1% cream: a novel, antibiotic-free agent approved for the treatment of patients with rosacea. Am Health Drug Benefits. 2015;8(Spec Feature):122–125.Laing R, Gillan V, Devaney E. Ivermectin — old drug, new tricks? Trends Parasitol. 2017;33(6):463–472. doi: 10.1016/j.pt.2017.02.004Trave I, Micalizzi С, Cozzani E, Gasparini G, Parodi A. Papulopustular Rosacea Treated with Ivermectin 1% Cream: Remission of the Demodex Mite Infestation Over Time and Evaluation of Clinical Relapses. Dermatol Pract Concept. 2022;12(4):e2022201. doi: 10.5826/dpc.1204a201Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103–1110. doi: 10.1111/bjd.13408Schaller M, Dirschka T, Kemeny L, Briantais P, Jacovella J, et al. Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded ATTRACT study. Dermatol Ther (Heidelb). 2016;6(3):427-436. doi: 10.1007/s13555-016-0133-6Huang H-P, Hsu C-K, Lee JY-Y. Rosacea with persistent facial erythema and high Demodex density effectively treated with topical ivermectin alone or combined with oral carvedilol. Dermatol Ther. 2021;34(2):e14899. doi: 10.1111/dth.14899Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16(9):909–916.Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78(12):649–652. doi: 10.1111/j.1365-2133.1966.tb12168.xValentin S, Morales A, Sanchez JL, Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129–140. doi: 10.2147/ccid.s4296van Zuuren EJ, Graber MA, Hollis S, Chaudhry M, Gupta AK, Gover M. Interventions for rosacea. Cochrane Database Syst Rev. 2005;20(3):CD003262. doi: 10.1002/14651858.CD003262.pub3Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12(2):1–5,9.Hofer T. Continuous “microdose” isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol. 2004;29(2):204–205. doi: 10.1111/j.1365-2230.2004.01472.xGollnick H, Blume-Peytavi U, Szabó EL, Meyer KG, Hauptmann P, Popp G, et al. Systemic isotretinoin in the treatment of rosacea — doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010;8(7):505–515. doi: 10.1111/j.1610-0387.2010.07345.xRademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol. 2013;54(3):157–162. doi: 10.1111/j.1440-0960.2012.00947.xРёкен М., Шаллер М., Заттлер Э., и др. Атлас по дерматологии. М.: Медпресс-Информ, 2014. С. 292–293. [Reken M, Schaller M, Sattler E, et al. Atlas of Dermatology. Moscow: MedPress-Inform; 2014. Р. 292–293. (In Russ.)]Рубинс А. Дерматовенерология: иллюстрированное руководство. М.: Изд-во Панфилова, 2011. С. 278. [Rubins A. Dermatovenereology. Illustrated guide. Moscow: Panfilov Publishing House; 2011. Р. 278. (In Russ.)]Yuan X, Li J, Li Y, Deng Z, Zhou L, Long J, et al. Artemisinin, a potential option to inhibit inflammation and angiogenesis in rosacea. Biomed. Pharmacother. 2019;117:109-181. doi: 10.1016/j.biopha.2019.109181Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatol Treat. 2018;29(3):310–313. doi: 10.1080/09546634.2017.1360991Logger JG, Olydam JI, Driessen RJ. Use of beta-blockers for rosacea-associated facial erythema and flushing: a systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020;83(4):1088–1097. doi: 10.1016/j.jaad.2020.04.129Kumar AM, Chiou AS, Shih YH, Li S, Chang ALS. An exploratory, open-label, investigator-initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. Br J Dermatol. 2020;183(5):942–943. doi: 10.1111/bjd.19172Самцов А.В. Акне и акнеформные дерматозы: монография. М.: ЮТКОМ, 2009. С. 208. [Samtsov AV. Acne and acneform dermatoses: monograph. M.: UTCOM; 2009. Р. 208. (In Russ.)]Аравийская Е.Р., Соколовский Е.В. Руководство по дерматокосметологии. CПб.: Фолиант, 2008. С. 632. [Araviyskaya ER, Sokolovsky EV. Guide to dermatocosmetology. Saint Petersburg: Foliant; 2008. Р. 632. (In Russ.)]Bharti J, Sonthalia S, Jakhar D. Mesotherapy with botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. J Am Acad Dermatol. 2018;S0190–9622(18):30808-9. doi: 10.1016/j.jaad.2018.05.014Kim MJ, Kim JH, Cheon HI, Hur MS, Han SH, Lee YW, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg. 2019;45(9):1155–1162. doi: 10.1097/DSS.0000000000001819Fan L, Yin R, Lan T, Hamblin MR. Photodynamic therapy for rosacea in Chinese patients. Photodiagnosis Photodyn Ther. 2018;24:82–87. doi: 10.1016/j.pdpdt.2018.08.005Sun Y, Chen L, Zhang Y, Gao X, Wu Y, Chen H. Topical photodynamic therapy with 5-aminolevulinic acid in Chinese patients with Rosacea. J Cosmet Laser Ther. 2019;21(4):196–200. doi: 10.1080/14764172.2018.1502455Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983;220(4596):524–527. doi: 10.1126/science.6836297Лазеро- и светолечение: пер. с англ. / под ред. Д.Дж. Голд-берга. М.: Рид Элсивер, 2010. С. 12. [Laser and light therapy / ed. be Goldberg DJ. Moscow: Reid Elsiver; 2010. Р. 12. (In Russ.)]Bernstein EF, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med. 2008;40(4):233–239. doi: 10.1002/lsm.20621Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg. 2009;35(6):920–928. doi: 10.1111/j.1524-4725.2009.01156.xBaek JO, Hur H, Ryu HR, Kim JS, Lee KR, Kim YR, et al. Treatment of erythematotelangiectatic rosacea with the fractionation of high-fluence, long-pulsed 595-nm pulsed dye laser. J Cosmet Dermatol. 2017;16(1):12–14. doi: 10.1111/jocd.12284Bernstein EF, Schomacker K, Paranjape A, Jones CJ. Pulsed dye laser treatment of rosacea using a novel 15 mm diameter treatment beam. Lasers Surg Med. 2018;50(8):808–812. doi: 10.1002/lsm.22819van Zuuren EJ, Fedorowicz Z, Tan J, van der Linden MM, Arents BW, Carter B, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181(1):65–79. doi: 10.1111/bjd.17590Sodha P, Suggs A, Munavalli GS, Friedman PM. A randomized controlled pilot study: combined 595-nm pulsed dye laser treatment and oxymetazoline hydrochloride topical cream superior to oxymetazoline hydrochloride cream for erythematotelangiectatic rosacea. Lasers Surg Med. 2021;53(10):1307–1315. doi: 10.1002/lsm.23439Alam M, Voravutinon N, Warycha M, Whiting D, Nodzenski M, Yoo S, et al. Comparative effectiveness of nonpurpuragenic 595-nm pulsed dye laser and microsecond 1064-nm neodymium:yttrium-aluminum-garnet laser for treatment of diffuse facial erythema: A double-blind randomized controlled trial. J Am Acad Dermatol. 2013;69(3):438–443. doi: 10.1016/j.jaad.2013.04.015Salem SA, Abdel Fattah NS, Tantawy SM, El-Badawy NM, Abd El-Aziz YA. Neodymium-yttrium aluminum garnet laser versus pulsed dye laser in erythemato-telangiectatic rosacea: Comparison of clinical efficacy and effect on cutaneous substance (P) expression. J Cosmet Dermatol. 2013;12(3):187–194. doi: 10.1111/jocd.12048Al-Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing. Dermatol Ther. 2020;33(6):e13976. doi: 10.1111/dth.13976Kelly A, Pai A, Lertsakdadet B, Choi B, Kelly KM. Microvascular effects of pulsed dye laser in combination with oxymetazoline. Lasers Surg Med. 2020;52(1):17–22. doi: 10.1002/lsm.23186Suggs AK, Macri A, Richmond H, Munavalli G, Friedman PM. Treatment of erythematotelangiectatic Rosacea with pulsed-dye laser and oxymetazoline 1.0% cream: a retrospective study. Lasers Surg Med. 2020;52(1):38–43. doi: 10.1002/lsm.23176Uebelhoer NS, Bogle MA, Stewart B, Arndt KA, Dover JS. A split-face comparison study of pulsed 532-nm KTP laser and 595-nm pulsed dye laser in the treatment of facial telangiectasias and diffuse telangiectatic facial erythema. Dermatol Surg. 2007;33(4):441–448. doi: 10.1111/j.1524-4725.2007.33091.xKwon HH, Jung JY, Lee W-Y, Bae Y, Park G-H. Combined treatment of recalcitrant papulopustular rosacea involving pulsed dye laser and fractional microneedling radiofrequency with low-dose isotretinoin. J Cosmet Dermatol. 2020;19(1):105–111. doi: 10.1111/jocd.12982